Defense Secretary Pete Hegseth ordered annual testosterone screening for all active-duty and reserve personnel aged 30 and older, and the medical establishment immediately reached for the brakes. The July 15 directive folds a hormone check into the Periodic Health Assessment troops already take. Treatment would be voluntary, recommended only if a military physician signs off. But five of six men's health experts contacted by Reuters said they were puzzled by the mandate and worried it could lead to unnecessary — even harmful — treatment, including infertility. The stake for ordinary Americans is simple: the military exists to fight and win wars, and any policy that affects readiness needs to answer one question — does it make the force more capable, or less?
The Guardian framed the mandate as yet another Trump-era healthcare move lacking scientific basis, lumping it with Hegseth's reversed flu vaccine mandate and HHS's shakeup of its vaccine advisory panel. The tone is clear: unserious people doing unscientific things. But that framing omits key context. The American Urological Association and the Endocrine Society do recommend testosterone supplementation only for patients with confirmed deficiency and symptoms — fatigue, decreased muscle mass, low bone density, erectile dysfunction. Dr. Kevin McVary, a urologist on the medical advisory board of Rugiet, a telehealth platform that sells testosterone supplements, told The Guardian that while patients report improved alertness and stamina on treatment, "the evidence is not concrete, and it comes from patients who were treated because they were symptomatic." Fair point. Overtreatment carries real risks.
What The Guardian buried: the military population is not the general population. As Newsweek reported, a 2020 study in the International Journal of Psychiatry in Medicine identified "Operator Syndrome" — hormonal dysfunction alongside traumatic brain injury, sleep disturbance, and depression in special operations careers. Blast exposure and chronic stress dysregulate the endocrine system. A population-based study of active-duty men found that traumatic brain injury more than doubled the odds of hypogonadism. Troops carry an unusually high burden of exactly the things that suppress testosterone: chronic stress, sleep deprivation, and head trauma. Dr. Ugis Gruntmanis, an endocrinologist at Dartmouth Hitchcock Medical Center, conceded the mandate provides an opportunity to collect data on younger men, even as he warned that widespread screening without preliminary study data puts "the carriage before the horse."
There's also the regulatory shift The Guardian glossed over. HHS Secretary Robert F. Kennedy Jr. has called declining testosterone in young men an "existential" problem. In June 2026, HHS asked the FDA to revise testosterone replacement therapy labels — striking language that discouraged treating age-related decline and narrowing prostate-cancer contraindications. That followed a December 2025 FDA expert panel urging broader indications and lighter restrictions, supported by the 5,200-man TRAVERSE trial finding no meaningful rise in cardiovascular events. The screening directive didn't come from nowhere.
And this isn't just about men. Hegseth said "service member," not "serviceman." Women produce testosterone too, and clinical evidence ties low levels in women to diminished energy, mood, cognition, and bone density. The mandate covers both sexes.
Even Democratic Rep. Jimmy Panetta of California pushed for a five-year Pentagon study of testosterone in special-operations forces during the last NDAA. It didn't survive final negotiations, replaced by a directed briefing. But Panetta's concern was the same: surveys of veterans and active-duty troops pointed to a link between service and hormonal decline.
The real tension isn't between science and ideology — it's between a medical establishment that defaults to caution and a military that needs to know whether its fighting force is hormonally compromised. The doctors say study first, screen later. Hegseth says screen now, study as you go. Both carry risks. The question is which risk the country can afford.
